INTRODUCTION
Intrinsic DNA damage response and cellular senescence have recently been implicated as major foundations of the barrier against tumor progression (Bartkova et al., 2006; Nardella et al., 2011; Ventura et al., 2007; Xue et al., 2007) . Whereas normal cells senesce primarily through the mechanism of replicative senescence-namely, progressive erosion of telomeres accompanied by double-strand breaks and a DNA damage response (DDR), most cancer cells evade this mechanism by virtue of persistent telomerase activity (Collado et al., 2007) . However, some cancer cells bear telomere dysfunction (Meeker et al., 2004) and most others are vulnerable to different senescence-provoking mechanisms, such as oncogene-induced senescence (OIS) and senescence associated with loss of certain tumor suppressors (Nardella et al., 2011) . Mechanistically, OIS is the best-characterized process; similar to replicative senescence, OIS induces DDR, with subsequent activation of p53 and p21, imposing growth arrest (Bartkova et al., 2006) . Mechanisms of OIS have been studied both in vitro and in vivo, indicating an essential role of cytokines and chemokines in sustaining senescence (Acosta et al., 2008; Kuilman et al., 2008) . The importance of senescence as a tumor barrier has been indicated in mouse models of tumorigenesis and is supported by Significance Nonsteroidal anti-inflammatory drugs (NSAIDs) have remarkable effects in suppressing carcinogenesis, yet their anticarcinogenic mechanism of action is largely elusive. Most human cancers that are affected by NSAIDs develop in tissues that do not display overt inflammation. Para-inflammation, defined as an intermediate between basal homeostasis and chronic inflammation, is implicated in chronic human diseases, such as diabetes mellitus and atherosclerosis. Here we characterize a senescence-inflammatory response (SIR) as a form of para-inflammation following a persistent DNA damage response. We show that the senescence process has paradoxical tumor promotion effect in a mouse model of intestinal cancer and describe a distinct mode of action of NSAIDs-suppression of SIR/para-inflammation. Studies of human intestinal polyps imply similar effects of para-inflammation in human neoplasia.
human tumor studies. With the exception of the universal marker senescence-associated b-galactosidase activity (SA-b-gal), there is apparently little in common between senescence phenotypes of different tissues, implying that certain senescence attributes would be tissue specific. Another factor implicated in most, but not all types of senescence is p53 (Leal et al., 2008) ; its inactivation is thought to eliminate senescence in vivo.
Whereas the bulk of accumulating data indicates that senescence impedes tumor progression, Campisi and colleagues documented an opposing function of senescence in tumorigenesis. Accordingly, senescent cells cocultured with tumor cells secrete cytokines, chemokines, and growth factors, denoted senescence-associated secretory phenotype (SASP), which facilitate tumor cell growth (Coppé et al., 2010a) . Xenotransplantation of senescent cells with fully malignant cancer cells markedly accelerates the rate of tumor formation in mice (Bartholomew et al., 2009; Bhatia et al., 2008; Coppé et al., 2010b; Krtolica et al., 2001; Liu and Hornsby, 2007) . However, whether senescence facilitates tumorigenesis in a nontransplanted tumor model and if senescence of the epithelial tumor progenitors themselves, rather than associated stromal cells, can also promote tumorigenesis is not known. Elucidating the mechanisms and effects of senescence in the context of an intact tissue is important because the protumorigenic function of senescence may explain the vastly increased frequency of cancer at old age and constitute a possible therapeutic target for cancer prevention and treatment.
RESULTS

CKIa Loss in Mouse and Human Benign Intestinal
Tumors Is Associated with Senescence and Growth Arrest CKIa ablation in the mouse gut epithelium (CKIa Dgut ) triggers extensive Wnt hyperinduction, yet Wnt-associated excessive proliferation and tumorigenesis are conspicuously absent and gut homeostasis is maintained (Elyada et al., 2011) . Thus, CKIa loss is distinguished from other modes of Wnt hyperactivation (e.g., APC ablation) by an extensive DDR, p53/p21-dependent growth arrest, and senescence, likely counteracting the proproliferative and protumorigenic effects of Wnt hyperinduction (Elyada et al., 2011) . CKIa down-modulation could therefore act as a safeguard mechanism to inhibit aberrant Wnt-induced growth processes.
To assess the pathophysiologic relevance of CKIa loss in precancerous lesions, we examined human and mouse intestinal tumors for CKIa expression with immunohistochemistry (IHC). Whereas CKIa expression was homogeneous across normal gut epithelium, heterogeneous expression was found in most tested adenoma regions in human (16 of 18) and APC Min/+ mouse (34 of 40) gut ( Figure 1A ; Figure S1A available online, respectively). Low CKIa-expressing foci were consistently KI67-low in both human and mouse polyps, indicating that affected cells exit the cell cycle ( Figure 1 ; Figure S1 ). Moreover, reduced CKIa staining in sequential sections of mouse adenomas also correlated with SA-b-gal activity ( Figure S1 ), indicating an association between CKIa loss, senescence, and growth arrest. Taken together, these data suggest that CKIa down-modulation could play a role in inducing senescence and growth arrest in premalignant colorectal tumors.
Absence of CKIa in the Mouse Gut Triggers a Distinct, Low-Grade Senescence-Associated Inflammatory Response Cellular senescence has distinct inflammatory features that function both to maintain the process via an autocrine loop (Bartek et al., 2008) and to affect neighboring cells via paracrine signaling (Acosta et al., 2008) . The senescence-inflammatory response (SIR) is partly related to the previously described senescence-associated secretory phenotype (SASP) and Cancer Cell senescence-messaging secretome (SMS) (Coppé et al., 2008; Kuilman and Peeper, 2009) , which vary from one cell type to another (Kuilman and Peeper, 2009 ). These programmatic inflammatory responses are distinguished from acute or chronic inflammatory reactions and harbor noninflammatory secretory mediators, such as growth factors and various receptor proteins (Acosta et al., 2008; Collado and Serrano, 2006; Coppé et al., 2008; Kuilman et al., 2008; Kuilman and Peeper, 2009) .
Per histology and IHC analysis, CKIa Dgut (knockout, KO) mice did not show any obvious signs of cellular inflammation: lymphocyte and macrophage numbers in the lamina propria were similar to, or even lower than wild-type (WT) and heterozygous (CKIa +/Dgut , Het) mice (Figure 2A ). Flow cytometry comparison of small bowel mucosal cell populations between CKIa Dgut and CKIa +/Dgut even showed a slight reduction in the abundance of immune/inflammatory CD45-positive cells (Figures 2B and 2C) . On the other hand, comparative RNA-seq analysis of CKIa Dgut versus WT and CKIa +/Dgut enterocytes, and further validation of individual genes with qRT-PCR and IHC analysis, revealed a marked increase in the expression of many immune and inflammatory genes ( Figures 2D and 2E) , along with the senescence markers SA-b-gal ( Figure 2F ), p19ARF, and the senescence-associated lysosomal abundance marker LAMP-2A (Cho and Hwang, 2011;  Figure 2G ). Among the upregulated inflammatory genes are soluble agents (e.g., Tnf and IL1rn), TNF-receptor family members (e.g., Opg and Troy), Toll-like receptors (Tlr; e.g., Tlr1 and Tlr2), interferon response genes (e.g., Ifit2 and Oas2), inflammatory enzymes (e.g., Pla2g2a, and Ptges), and transcription factors (e.g., Sox17 and Rel). A list of the inflammation and senescenceassociated genes representing SIR is depicted in a heatmap ( Figure 2D ), indicating the relative gene expression of CKIa KO and CKIa Dgut ;p53 Dgut double knockout (DKO) enterocytes (Elyada et al., 2011) compared to CKIa Het enterocytes. A comparison of the SIR list to a compilation of SASP/SMS based on previous studies (Acosta et al., 2008; Collado and Serrano, 2006; Coppé et al., 2008; Kuilman et al., 2008; Kuilman and Peeper, 2009 ) shows a relatively small overlap between SIR and SASP ( Figure 2D ), suggesting that SIR and SASP may have some common features, yet are mostly distinct. Furthermore, in accordance with the paucity of many secreted factors, particularly chemokines in the CKIa KO and DKO gut, gene set enrichment analysis comparison of SIR and SASP mostly indicates a negative correlation ( Figure S2 ).
To test whether the inflammatory component of SIR is a cellautonomous property of senescence-marked enterocytes, gut sections were analyzed with IHC and immunofluorescence (IF) for senescence markers, of which prostaglandin E2 synthase (PTGES, also known as microsomal oxidoreductase, mPGES1), an inflammatory enzyme that is also a strong oncogene-induced senescence indicator (Kuilman et al., 2008) , was highly induced in CKIa-ablated gut ( Figure 2G ). The inflammatory enzyme phospholipase A2 (sPLA2; Fijneman et al., 2009) , highly scored in the RNA-seq-derived heatmap (Pla2g2a), is also strongly expressed in CKIa-deficient intestinal sections ( Figure 2G ), and double IF of PTGES and sPLA2 demonstrates a complete expression overlap between these two genes ( Figure 2H) . It therefore appears that the inflammatory response is a cellautonomous property of senescing cells.
SIR Effects in the Absence of p53 and p21
Several studies have attributed cellular senescence to the activation of p53 and p21; Pten loss-induced senescence was abrogated in p53-deficient mice and Ras oncogene-induced senescence was observed in liver tumors upon p53 reactivation (Nardella et al., 2011; Xue et al., 2007) . To assess the role of p53 and p21 in the cellular senescence induced in CKIa Dgut , we examined SIR components in doubly deficient CKIa Dgut ;p53 Dgut and CKIa Dgut ;p21 À/À mice (CKIa;p53 or CKIa;p21 DKO, respectively; Elyada et al., 2011) . Surprisingly, the senescence indicators SA-b-gal, p19ARF, PTGES/mPGES1, and the inflammatory gene set remained prominent in both CKIa;p53 DKO and CKIa;p21 DKO gut ( Figures 3A and 3B ). p21 is a potent p53induced growth suppressor in most cell types (Abbas and Dutta, 2009 ) and is the most prominent cyclin-dependent kinase inhibitor associated with CKIa KO-induced senescence in the mouse gut (Elyada et al., 2011) . As expected, SA-b-gal activity and BrdU incorporation were mostly mutually exclusive in the CKIa Dgut bowel ( Figures 3C and 3D ), yet unexpectedly concur in both CKIa;p21 and CKIa;p53 DKO intestines ( Figures 3C and 3D ). The uncoupling of SA-b-gal activity from growth arrest and the dramatic intestinal carcinogenesis characterizing DKO mice suggest that SIR loses its cancer-protective role in the absence of p21, either primarily or secondarily to p53 deficiency. IHC Gene symbols are color-coded to indicate genes designated as SIR genes (red), SASP genes (blue), or both (purple). The SASP gene set was compiled from the literature (Acosta et al., 2008; Coppé et al., 2008; Kuilman et al., 2008; Kuilman and Peeper, 2009) . SIR genes were defined as senescence-and inflammation-associated genes that showed at least 2-fold upregulation averaged in both conditions (KO and DKO). (E) Quantitative real-time PCR (qRT-PCR) analysis of inflammatory genes in IECs isolated from CKIa KO mice at different time points following KO induction: day 2 (n = 4), day 5 (n = 6), and day 8 (n = 5), normalized to CKIa Het mice (n = 8; mean ± SEM). *p < 0.05 (compared to day 2). KO, CKIa; p21, and CKIa; p53 DKO sections shown in (C). n = 93, n = 58, and n = 72, respectively; mean ± SEM. *p = 0.04, y p = 0.07. (E) Double staining of SA-b-gal (blue) and PROX1 (brown) in invasive clusters of the small intestine in a representative intestinal cryo-section of a CKIa;p21 DKO mouse. Black triangles mark the double-positive clusters (n = 213/216 clusters). Counterstain: nuclear fast red. expression analysis in CKIa;p21 DKO mice often shows overlapping immunostaining of the senescence indicators SA-b-gal and the transcription factor PROX1 ( Figure 3E ), which is tightly associated with high-grade dysplasia and invasive phenotype in human and mouse gut (Elyada et al., 2011; Petrova et al., 2008) , raising the hypothesis that under particular circumstances, such as loss of p53, paracrine effects of SIR might promote invasion and carcinogenesis. This assumption would be in line with in vitro studies by Coppé and colleagues showing that senescence may drive tumorigenesis via paracrine effects of a senescence-associated secretory phenotype (SASP; Coppé et al., 2008) . Yet, unlike the SASP effects, the entire ground of SIR action could be the epithelium proper, not requiring additional pathology in the stromal component.
Senescing Epithelial Organoids Are Rescued by p53 Deficiency, while Assuming a Transformed Phenotype
To study the effects of senescence in an isolated tissue composed solely of epithelial cells, we induced CKIa deletion in gut epithelial organoids ex vivo. Cellular senescence is a fundamental protective mechanism, but its physiologic role in different tissues, or different cell types in a given tissue, is mostly obscure. Epithelial organoids were prepared from floxed CKIa and doubly floxed CKIa;p53 mice and treated in culture with 4-hydroxy-tamoxifen (4OHT), producing single CKIa deletion (SKO) and double CKIa;p53 deletion (DKO), respectively (Figure S3A) . Similar to the effect in gut mucosa, both SKO and DKO organoids activate senescence markers, such as p19ARF, LAMP-2A (Cho and Hwang, 2011; Collado et al., 2007) , and the SIR gene set, in response to CKIa ablation ( Figure 4K ). Notably, both SKO and DKO organoids acquired a different morphology compared to their nondeleted floxed counterparts: a spherical compact structure, without the crypt-like outpockets that characterize WT and nondeleted organoids ( Figure 4H ). BrdU incorporation analysis of the organoids in comparison to their nondeleted counterparts indicated that while proliferation was restricted to the crypt-like outpockets in the WT organoids (CKIa flfl and CKIa fl/fl ;p53 fl/fl ), it encompassed the entire organoid volume in DKO cultures ( Figure 4K ), indicating that following ablation, DKO organoids acquired a proliferative crypt phenotype that characterizes colonic tumors (Sato et al., 2011) .
Intestinal organoids are purely epithelial and do not bear lamina propria and other stromal components. Therefore, invasiveness cannot be observed in organoids as part of the ''transformed'' phenotype. Nevertheless, we could measure expression of genes belonging to the proinvasive gene expression signature (denoted PSIS), characterizing invasive epithelial foci at the lamina propria of DKO mice (Elyada et al., 2011) . Several PSIS genes were upregulated following tamoxifen induction of doubly floxed CKIa;p53 organoids ( Figure S3B ), and immunostaining of DKO organoids revealed a remarkable induction of the PSIS gene Prox1, compared to control ( Figure 4L) . It therefore appears that the ablation of p53 switches the fate of the senescing intestinal organoids from rapid decay to immortalization with a transformed phenotype, including bulk proliferation, loss of normal crypt-villous architecture, and acquisition of proinvasive properties (expression of PSIS markers).
Inflammatory Mediators Are Needed to Maintain the Transformed Phenotype of DKO Organoids Similar to the CKIa-deleted gut mucosa, organoid senescence is associated with the expression of a set of inflammatory mediators ( Figure 4D ). To assess the contribution of the inflammatory repertoire to the organoid fate, we treated SKO and DKO organoids with the nonsteroidal anti-inflammatory drug (NSAID) sulindac and with the IkB kinase (IKK) inhibitor BOT64 (Kim et al., 2008) . Treated SKO organoids showed significant reduction in the senescence markers LAMP-2A and p21 (Figures 5A-5C ) and regained some incorporation of BrdU ( Figure 5D ). Accordingly, NSAID-treated SKO organoids presented a 20% prolonged life span compared to their nontreated counterparts ( Figures 5E and 5F ). Remarkably, treatment of DKO organoids with anti-inflammatory drugs mitigated the proliferative crypt phenotype, restoring the normal budding phenotype observed in WT or CKIa fl/fl ;p53 fl/fl organoids ( Figures 6A-6D ), in association with SIR gene inhibition ( Figure 6E ). This reversion was accompanied with a redistribution of BrdU incorporation from the spheroid core body to the periphery and outpockets ( Figure 6F ) and a marked suppression of PSIS induction (Figures S4A-S4C ). Sulindac-dependent inflammatory and invasive signature (PSIS) suppression was apparent as early as 16 hr after treatment initiation and lasted at least 5 days ( Figures S4A and S4B ). IHC analysis in treated DKO organoids confirmed PSIS suppression by NSAIDs, showing markedly reduced expression of PROX1 ( Figure 6G ); residual PROX1 expression was mainly observed at the budding outpockets, corresponding to its occasional expression in the bottom of intestinal crypts (Petrova et al., 2008) . Collectively, this implies that both the aberrant growth properties and the invasion propensity of DKO organoids are SIR-dependent processes, taking place in a stroma-free epithelial tissue.
DKO organoids were found to express significantly higher levels of tumor necrosis factor (TNF) than organoids isolated from APC Dgut (APC KO) or WT mice ( Figure 6H ). To assess the role of TNF in crypt organoid biology, we treated TNF-producing DKO organoids and control APC KO organoids with anti-TNF neutralizing antibodies. Anti-TNF consistently suppressed the growth of DKO organoids by 15%-20% (size-wise and BrdU incorporation at day 4), whereas it had no effect on APC KO organoids ( Figures S4D and S4E) . Notably, once organoids grow, they may be mostly secluded from antibody effects (Sutherland et al., 1987) , possibly explaining the small, yet consistent and highly significant effect. In line with these findings, exogenous TNF treatment had a robust effect on WT organoids: it induced aberrant growth and morphologic changes resembling the untreated DKO organoids; the ratio of budding organoids was highly reduced following TNF treatment, BrdU incorporation was redistributed from outpockets to the central sphere and WT organoids acquired a proliferative crypt phenotype by day 4 (Figures 6I and 6J) . Altogether, these data suggest that in the absence of p53, contrary to the expected growth arrest, SIR promotes an abnormal proliferative phenotype and an invasion spur both in vivo and in purely epithelial intestinal organoid cultures.
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NSAIDs Abolish the Procarcinogenic Effect of SIR In Vivo Based on the effects of SIR in organoid cultures, we tested whether SIR has a role in carcinogenesis in vivo. First we tested the effect of sulindac on CKIa KO mice and found that whereas it repressed SIR as evident by SA-b-gal activity, p19ARF, p21, and the SIR inflammatory genes ( Figure S5A ; Elyada et al., 2011) , SKO intestinal homeostasis was maintained. This is probably due to balanced Wnt and p21 signaling because both the protumorigenic and countertumorigenic signaling arms were similarly repressed by the NSAID treatment (Figure S5B) . In contrast, sulindac treatment spared both DDR and p53 activation ( Figures S5C and S5D ). Next, we treated CKIa;p21 DKO mice, which otherwise succumb to massive intestinal carcinogenesis within less than 2 weeks (Elyada et al., 2011) , with three anti-inflammatory agents having different mechanisms of action: sulindac, BOT64, and BV6, a TNF signaling inhibitor (Varfolomeev et al., 2007 (Varfolomeev et al., , 2012 . All three reagents inhibited SIR in the gut of DKO mice, evident by a reduction in SA-b-gal activity ( Figures 7A and 7B ), reduced expression of PTGES/mPGES1 and sPLA2 inflammatory mediators ( Figure S5E ), and a decrease in the levels of the inflammatory gene set ( Figure S5F ) and p21 expression ( Figure S5G) . Concomitantly, anti-inflammatory treatment suppressed the expression of multiple proinvasive genes, which characterizes the malignant lesions in this mouse model (Elyada et al., 2011 ; Figures 7C-7E ; Figures S5G-S5I) , and subsequently suppressed enterocyte proliferation and carcinogenesis of CKIa;p21 DKO mice ( Figures 7C-7F ; Figure S5J ). Treatment with BV6 did not augment the already induced caspase-3 activation in DKO mice ( Figure S5K ), indicating that its anticarcinogenic effect is not via induction of apoptosis.
Notably, whereas Wnt target gene expression was suppressed by sulindac ( Figures S5B and S5L) , it was not affected by BV6 and only mildly repressed by BOT64 ( Figure S5M ), indicating that the carcinogenic arrest was not achieved via Wnt inhibition. In addition, all anti-inflammatory treatments spared DDR and p53 activation ( Figures S5N-S5P ). Collectively, these data indicate that the anticarcinogenic effect of anti-inflammatory agents is via targeting SIR, distinct from Wnt/b-catenin suppression.
DISCUSSION
Inflammation is a protective response, primarily known to confront and eliminate pathogens. However, it is often entwined with a growth response that is needed for restoring tissue loss following injury and infection. It thereby fulfills two complementary functions, countering infection and promoting tissue growth, best evident in wound healing (Ben-Neriah and Karin, 2011) . Notably, hints of a relationship between inflammation and abnormal cell growth can be found very early in metazoan evolution, perhaps as early as corals, which frequently exhibit abnormal growths much like tumors (Squires, 1965) . Tumors have many characteristics in common with wound healing and indeed were described as ''wounds that won't heal'' (Dvorak, 1986) . Whereas inflammation is emerging as one of the hallmarks of cancer (Hanahan and Weinberg, 2011) , its role in most tumors is not well understood. Only a minority of solid tumors is associated with overt inflammation (Coussens and Werb, 2002) , but long-term treatment with NSAIDs is remarkably effective in reducing intestinal tumorigenesis in a mouse model (Beazer-Barclay et al., 1996) and mortality rates associated with major human solid tumors, by up to 75% (Burn et al., 2011; Chan et al., 2009; Rothwell et al., 2010) . These figures indicate that inflammation may have many unrecognized faces, of which an indolent course may be far more important factor in cancer than previously appreciated. Medzhitov has coined a low-grade inflammatory response ''para-inflammation,'' referring to an adaptive response due to tissue stress or malfunction. This response was proposed as an intermediate between the basal homeostatic state and a classic inflammatory response and hypothesized to underlie chronic inflammatory conditions that are associated with common human diseases, such as atherosclerosis, diabetes mellitus, and neurodegeneration (Medzhitov, 2008) . Based on our study, we presume that this theoretical concept may be extended to another disease category, now with experimental evidence, implicating para-inflammation in tumorigenesis.
Whereas classical inflammatory reactions are primarily associated with cell-exogenous insults, para-inflammation could originate upon cell-endogenous insults; prominent examples Figure S3 .
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Senescence Switch Promotes Colorectal Cancer are DNA damage and senescence, both of which are documented in colorectal tumorigenesis (Bartek et al., 2008; Bartkova et al., 2006) . However, it is unclear why colorectal polyps manifest DDR and senescence. Although APC mutation-induced Wnt hyperactivation could be a source of OIS in colorectal polyps, senescence is not restricted to the highly hyperactivated proliferating zones of the polyp (Bartkova et al., 2006; Kuilman et al., 2008) , nor have we observed evidence for senescence or DDR in APC-mutated aberrant crypt foci (pre-polyp regions; data not shown). We therefore maintain that patchy CKIa loss in human and mouse APC-mutated, colorectal polyps has a distinct role beyond Wnt activation, likely incorporating DDR for inducing senescence. Such Wnt-DDR synergism prevails with intentional CKIa ablation in the mouse gut and may therefore recapitulate a human pathophysiologic phenomenon. It is likely that CKIa ablation as a single genetic alteration may in fact mimic the cumulative effect of multiple genetic alterations in human colorectal cancer, many of which, like the Ras pathway mutations, culminate in DDR and senescence (Collado and Serrano, 2010; Figure 8) .
Inflammatory mediators secreted from senescent cells have been documented to modulate the tumor microenvironment (legend continued on next page)
Senescence Switch Promotes Colorectal Cancer resulting in two apparently opposing roles: on one hand, tumor inhibition via maintenance of prolonged to indefinite growth arrest and immune clearance of the senescent cells (Bartkova et al., 2005; Chen et al., 2005; Guerra et al., 2011; Kang et al., 2011; Reimann et al., 2010; Ventura et al., 2007; Xue et al., 2007) , and conversely, tumor promotion via attraction of tumor-supporting inflammatory cells, such as macrophages and fibroblasts (Krtolica et al., 2001; Rakhra et al., 2010) and angiogenesis (Sparmann and Bar-Sagi, 2004) . We now show how a senescence-associated para-inflammatory response shifts its role from an antitumorigenic effector to a procarcinogenic one, depending on the integrity of p53 and p21; in the presence of functional p53 and p21, gut epithelial SIR is coupled to growth arrest, whereas loss of either p53 or p21 uncouples the two complementary processes and provokes epithelial invasion into the lamina propria ( Figure 3C ). This may herald the progression of a benign overgrowth to malignancy. Notably, the SIR phenotype in CKIa-deficient gut is distinct from other inflammatory reactions and bears only partial relationship to the previously described SASP ( Figure 2D) . Epithelial SIR features a distinct inflammatory profile that lacks most of the chemokines, a hallmark of SASP, and accordingly is devoid of a cellular inflammatory infiltrate. A similar process may commonly characterize human adenomatous polyps with patchy CKIa loss and no obvious inflammatory infiltrate. This dual-purpose autonomous inflammatory function is best evident in pure epithelial organoid cultures derived from CKIa-deficient (SKO) and CKIa;p53 doubly-deficient (DKO) gut epithelium, which undergo senescence, generate their own internal microenvironment, upregulate immune receptors, and produce TNF. Yet, the fate of SKO and DKO organoids is quite distinct and is remarkably similar to that of the mucosa from which they are derived: whereas the senescence process in SKO organoids culminates in growth arrest as expected; in DKO organoids, it actively drives a proliferative tumor-like crypt phenotype (Sato et al., 2011) . Likewise, treatment of WT organoids with TNF results in a similar proliferative crypt morphology. Finally, treatment of the organoids with anti-inflammatory agents moderates both the growth promotion and proinvasive properties driven by SIR, in line with their robust anticarcinogenic effect in DKO mice. We show here that NSAID treatment strongly suppresses SIR and abolishes both the tumor-like phenotype of DKO organoids and carcinogenesis in DKO mice. Particularly robust is the suppression of PSIS genes and certain proinflammatory enzymes, notable among which are phospholipase A2 (Pla2g2a), lactoperoxidase (Lpo), and the prostaglandin E2 synthase Ptges/ mPGES1, a microsomal oxireductase that converts the COX-2 product PGH2 to PGE2. Prostaglandin E2 is associated with invasiveness in many types of cancer (Greenhough et al., 2009 ), yet the anticarcinogenic effect of NSAIDs is mostly related to COX-2 inhibition (Wang and Dubois, 2010) . Ptgs2, encoding COX-2, is not a SIR gene, and unlike Ptges, it is not expressed in the gut epithelium, but in the lamina propria (data not shown). Interestingly, COX-2 is dispensable for DSS/AOM-induced colon cancer in a mouse model (Ishikawa and Herschman, 2010) , possibly implying that in para-inflammation-associated cancer, PTGES, rather than COX-2, could be the key carcinogenesispromoting target for NSAID inhibition. We therefore propose that epithelial SIR/para-inflammation is a major factor in colorectal tumor progression and its suppression may represent an important mechanism for the anticarcinogenic effect of NSAIDs (Figure 8) ; other anti-inflammatory reagents, such as IKK and TNF antagonists, may also achieve similar SIR-targeted anticarcinogenic effects.
EXPERIMENTAL PROCEDURES
Human Samples IHC studies on human intestinal polyp sections were approved by the institutional review board of the Hadassah-Hebrew University Medical Center (HMO-0109-11), verifying that informed consent is not required.
Mouse Breeding and Genotyping
CKIa fl/fl ;Villin-Cre-ER T2 (CKIa Dgut ), CKIa fl/fl ;p53 fl/fl ;Villin-Cre-ER T2 (CKIa Dgut ; p53 Dgut ) and CKIa fl/fl ;p21 À/À ;Villin-Cre-ER T2 (CKIa Dgut ;p21 À/À ) mice were generated as previously described (Elyada et al., 2011) . APC Min/+ (Harlan) mice were sacrificed at 3-5 months of age. Genotyping primers are listed in the Supplemental Experimental Procedures. Mice were kept under specific pathogen-free conditions at the Hadassah Medical School of the Hebrew University. All mouse experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the Hebrew University-Hadassah Medical School and performed in accordance with this committee's guidelines.
Tamoxifen Administration; Sulindac, BV6, and BOT64 Treatments; BrdU Labeling; and Tissue Preparation Mice were injected with 150 mg/kg tamoxifen (Sigma) subcutaneously, six injections every other day. Sulindac (Sigma) was administered in the drinking water at 0.6 g/l, 1 week before the first tamoxifen injection and throughout the 2 weeks of KO induction for a total period of 3 weeks. BV6 (Genentech) was injected intraperitoneally at 10 mg/kg, every other day, from day 2 of KO induction. BOT64 (Santa Cruz) was injected intraperitoneally at 30 mg/ kg, every day, from day 2 of KO induction. One to two days after the last tamoxifen injection, mice were injected intraperitoneally with 10 ml/g of 5-bromo-2deoxyuridine (BrdU; GE Healthcare) and sacrificed 2 hr later, on day 10-12 of KO induction. Intestine was fixed in 4% formaldehyde for paraffinembedded sections (FFPE), or immediately embedded in Tissue-Tek OCT (I) Relative ratio of nonbudding WT organoids following a 4-day treatment with 100 ng/ml exogenous TNF compared with untreated WT controls (± SD; n R 60). *p = 0.002. (J) BrdU labeling of WT organoids following a 3-day treatment with 1,000 U/ml exogenous TNF compared with untreated WT controls. White arrows indicate BrdU-positive budding outpockets. See also Figure S4 .
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Senescence Switch Promotes Colorectal Cancer Compound (Sakura) and frozen at À80 C for frozen sections. Intestinal epithelial cells (IECs) were isolated as previously described (Elyada et al., 2011; Greten et al., 2004; detailed in the Supplemental Experimental Procedures) .
Histology, Immunohistochemistry, Immunofluorescence, and Senescence-Associated b-Galactosidase Analysis Five micrometer sections were cut for hematoxylin and eosin staining (H&E) and IHC. Antibodies that were used in tissue staining are listed in the Supplemental Experimental Procedures. Diaminobenzidine chromogen (LabVision) was used for detection of IHC. Hematoxylin was used as nuclear counterstain for IHC. Senescence-associated b-galactosidase (SA-b-gal) staining was performed on 10 mm sections of OCT-embedded frozen tissue, and the procedure and antibodies conditions are detailed in the Supplemental Experimental Procedures.
Intestinal Crypt Cultures
Intestinal crypts from WT, APC KO, CKIa KO, and CKIa;p53 DKO mice were isolated on the basis of the previously published methods (Sato et al., 2009) . Culturing of crypts is detailed in the Supplemental Experimental Procedures. KO Induction was carried out by adding 300 nM 4-hydroxytamoxifen (4OHT; Sigma) for 48 hr to organoid culture medium. Selection for organoids with active Wnt/b-catenin pathway was done by splitting the 4OHT-induced organoids and culturing them without growth factors in the medium. Organoids were treated with TNF (R&D, 100 ng/ml), neutralizing goat anti-mouse TNF antibody (R&D, 2.5 mg/ml), sulindac (Sigma, 100 mM or 500 mM), and BOT64 (Santa Cruz, 2.5 mM). The ratio of dead or nonbudding organoids was calculated on day 4. Whole-mount staining of organoids was done in four-well chamber slides (BD Biosciences) or on round coverslips in a 24-well plate. Incubation with 10 uM BrdU was performed for 16 hr. Incubation with the primary antibody was performed overnight at 4 C. More details can be found in the Supplemental Experimental Procedures.
FACS, Western Blotting, and RNA Analysis
Immune cells (CD45.2-positive population) were sorted from the IEC preparation using anti-CD45.2 antibody (1:200; BD Pharmingen). Wholecell protein extracts were isolated from IECs or intestinal crypt organoids and analyzed with western blotting using a standard protocol. Antibodies that were used are listed in the Supplemental Experimental Procedures. HRP-linked secondary antibodies were used for detection (1:10,000; Jackson). Blots were developed using ECL (GE Healthcare). Total RNA was extracted from IECs using TRI-reagent (Sigma) and phenol/chloroform methods, and from crypt cultures using the NucleoSpin RNA II Kit (Macherey-Nagel). Reverse transcription was done using M-MLV-RT (Invitrogen), and mRNA expression levels were measured with qRT-PCR using SYBR-Green (Invitrogen) in a 7900HT Fast Real-Time PCR system (ABI). Sequences of RT-PCR primers are listed in the Supplemental Experimental Procedures. Relative quantities of gene transcripts were analyzed in qBase 2.2 software and normalized to ubiquitin C, hypoxanthine-guanine phosphoribosyltransferase, and/or glyceraldehyde-3-phosphate dehydrogenase transcripts.
RNA-seq Analysis
For RNA-seq, total RNA from IECs of CKIa +/Dgut (Het), CKIa Dgut (KO) and CKIa Dgut ;p53 Dgut (DKO) mice was prepared as previously described, and samples from three mice per genotype were pooled together. The RNA of each genotype group was processed with the mRNA Sequencing Kit (Illumina) and duplicate samples were subjected to multiplex sequencing using the Illumina HiSeq2000 platform, according to the manufacturer's protocol. Analysis protocol is detailed in the Supplemental Experimental Procedures. The RNA-seq full data can be found at http://www.ebi.ac.uk/arrayexpress/ experiments/E-MTAB-1683/.
More details can be found in the Supplemental Experimental Procedures. CKIa loss or the accumulation of several oncogenic mutations results in a persistent DDR in normal epithelial tissue. Persistent DDR triggers SIR, a form of para-inflammation, an intermediate between basal homeostasis and chronic inflammation, which is confined to the epithelial tissue itself. In p53proficient tissue, SIR, accompanied by p53 activation, results in p21 activation, counterbalancing the excessive proliferation due to the oncogenic effects, and thus tissue homeostasis is maintained. However, when p53 is mutated or lost, p21 fails to be activated, resulting in a breach of homeostasis, hyperproliferation, invasion, and carcinogenesis. NSAID treatment moderates para-inflammation; consequently both the proproliferative (e.g., Wnt activation) and the proinvasive drive (e.g., PSIS expression) are suppressed, thus helping to regain homeostasis.
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